Story thread · 2 reports / 2 sources
Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
biopharmadive.com · 9h · first report
How the coverage leans
Across 2 sources · syndicated copies counted once
The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.
The coverage
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.